KyungDong Pharm home
Prescription Medicines

Loxonal Tab.

Product Category
Analgesics, Antipyretics & Anti-inflammatory Medicines
Active Ingredients
Loxoprofen sodium hydrate
Appearance
A white to pale yellow, round tablet.
Reimbursement Code
648100560
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
- Active ingredient: Loxoprofen sodium hydrate (JP)----68.1mg (60mg as anhydrous)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, magnesium stearate, low-substituted hydroxypropyl cellulose

2. Effectiveness
1. Anti-inflammatory and analgesic treatment of the following diseases and symptoms
Chronic rheumatoid arthritis, osteoarthritis (degenerative arthritis), back pain, periarthritis of the shoulder, glenohumeral syndrome
2. Anti-inflammatory and analgesic after surgery, trauma and tooth extraction
3. Fever relief and pain relief for the following diseases
Acute upper respiratory tract inflammation (including acute upper respiratory tract inflammation with acute bronchitis)

3. Dosage and dosage
1. In case of efficacy 1 and 2
○ Adults: Orally administer 60 mg at a time as loxoprofen sodium (anhydrous) three times a day. For one-time therapy, 60 to 120 mg is administered orally at a time.

2. In case of efficacy effect 3
○ Adults: Orally administer 60 mg once as loxoprofen sodium (anhydrous). In principle, it can be administered twice a day, up to a maximum of 180 mg per day.

It is advisable to avoid taking it on an empty stomach.
Increase or decrease appropriately depending on symptoms.

4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.

2. Do not administer to the following patients.
1) Patients with peptic ulcer
2) Patients with severe blood abnormalities
3) Patients with severe liver impairment
4) Patients with severe renal impairment
5) Patients with severe heart failure
6) Patients with hypersensitivity to this drug or its components
7) Patients with asthma, urticaria, allergic reactions or a history of such reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In such patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
8) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
9) Pregnant women in the last trimester of pregnancy
10) Nursing mothers
11) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
12) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients.
1) Patients with a history of peptic ulcer
2) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently being treated with peptic ulcers such as misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
3) Patients with blood abnormalities or history thereof
4) Patients with hepatic impairment or its history
5) Patients with renal impairment or its history
6) Patients with fluid retention or heart failure
7) Patients with a history of hypersensitivity reaction
8) Patients with bronchial asthma
9) Elderly people
10) Patients with high blood pressure
11) Patients with blood coagulation disorders or receiving anticoagulants
12) Patients taking diuretics or ACE inhibitors
13) Pregnant women in the early or middle stages of pregnancy or women who may be pregnant

4. Adverse reactions
1) Hypersensitivity reaction: Occasionally rash, itchiness, fever, or in rare cases, hives may occur. If these symptoms appear, discontinue administration.
2) Shock and anaphylaxis-like symptoms may occur, so observe thoroughly and if abnormalities (hives, difficulty breathing, low blood pressure, etc.) are confirmed, stop taking the drug and take appropriate measures.
3) Digestive system: Gastrointestinal bleeding such as peptic ulcer, perforation, or hematemesis from the small intestine or large intestine may occur, and shock may occur along with it. If these symptoms appear, immediately stop administration and take appropriate measures. Additionally, abdominal pain, stomach discomfort, loss of appetite, nausea, vomiting, diarrhea, constipation, chest discomfort, indigestion, stomatitis, thirst, and abdominal distension may occur.
4) Intestinal perforation may occur, so if special symptoms, including upper abdominal pain or abdominal pain, are detected, administration should be stopped immediately and appropriate measures should be taken.
5) Mental nervous system: Sometimes drowsiness, numbness, dizziness, and rarely headaches may occur.
6) Blood system: In rare cases, anemia, hemolytic anemia, decreased white blood cells, decreased platelets, and sometimes increased eosinophils may occur.
7) Congestive heart failure may occur, so observe thoroughly, and if any abnormalities are found, immediately stop administration and take appropriate measures.
8) Liver: Liver dysfunction (jaundice, increased ALT, AST, ALP, ϒ-GTP, etc.) and fulminant hepatitis may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if adverse reactions occur.
9) Kidney: In rare cases, acute renal failure, nephrosis syndrome, or interstitial nephritis may occur. If abnormalities are found, take appropriate measures, such as discontinuing administration. Caution should be exercised as hyperkalemia may occur in patients with acute renal failure.
10) Urinary system: In rare cases, hematuria and proteinuria may occur.
11) Respiratory system: In rare cases, interstitial pneumonia accompanied by fever, resolution, difficulty in breathing, abnormal chest Since acute respiratory disorders such as asthma attacks may occur, sufficient observation should be conducted and if adverse reactions occur, administration of this drug should be discontinued and appropriate measures taken.
12) Skin: Mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), erythema multiforme, and acute generalized pyknotic pustulosis may occur, so observe thoroughly. If any adverse reactions occur, immediately stop administration and take appropriate measures.
13) Others: Occasionally, edema, chest pain, anxiety, fatigue, and in rare cases, palpitations may occur.
14) As aseptic meningitis (fever, headache, nausea/vomiting, neck stiffness, clouding of consciousness, etc.) may occur, sufficient observation should be conducted. If any adverse reactions occur, administration should be immediately discontinued and appropriate measures taken (adverse reactions are especially likely to occur in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD).)
15) As a result of analyzing domestic voluntary adverse event reporting data (1989-2013), the adverse events reported in statistically significantly higher numbers compared to adverse events occurring in other drugs for which adverse events were reported were as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
· Angioedema
· Facial edema (periocular edema, oral edema)
16) Stenosis and occlusion of the small and large intestine: As an adverse event after overseas marketing, stenosis and occlusion of the small and large intestine have been reported in association with ulcers in the small or large intestine. During treatment with this agent, patients should be carefully observed, and if symptoms such as nausea, vomiting, abdominal pain, or abdominal distension are detected, administration should be stopped immediately and appropriate treatment should be taken.
17) As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-June 2017), the newly confirmed adverse events are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
? Skin and subcutaneous tissue system-DRESS syndrome

5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using this drug for chronic diseases, consider the following:
(1) Patients taking this drug for a long period of time should regularly conduct clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping the medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
4) When using this drug for acute illness, consider the following:
(1) Administer taking into account the degree of acute inflammation, pain, and fever.
(2) In principle, avoid long-term administration of the same drug.
(3) If there is a causal treatment, perform it.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions.
Excessive decrease in body temperature, collapse, cooling of extremities, etc. may occur, so pay close attention to the patient's condition after administration, especially for elderly patients with high fever or patients suffering from wasting diseases.
6) Due to the pharmacological properties of this drug, there is a risk of delaying the diagnosis of infectious complications under painful and non-infectious conditions by making fever and other symptoms and signs of inflammation invisible. When this drug is used for inflammation caused by infection, it should be administered carefully and under sufficient observation, along with an appropriate antibacterial agent if necessary at the doctor's discretion.
7) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
8) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
9) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
10) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
11) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
12) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values ​​may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or for patients with abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration of this drug should be discontinued.
13) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
14) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
15) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
19) Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) may have an increased risk of developing aseptic meningitis when taking this drug.

6. Interaction
1) Do not administer in combination with other non-steroidal anti-inflammatory analgesics as the risk of adverse reactions may increase.
2) Since it may enhance the action of the following medicines, when taking these medicines, administer with caution, such as reducing the amount of these medicines. : Sulfonylurea hypoglycemic agents (tolbutamide, etc.), new quinolone antibiotics (enoxacin, etc.)
3) ACE inhibitors and angiotensin II receptor antagonists: Since the antihypertensive effect of ACE inhibitors may be reduced by non-steroidal anti-inflammatory drugs, such interactions should be kept in mind when coadministering this drug with ACE inhibitors and angiotensin II receptor antagonists.
4) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
5) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
6) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when administering non-steroidal anti-inflammatory drugs and lithium together, the action of lithium may be enhanced, so administer with caution, such as reducing the dose of lithium and carefully observing signs of toxicity.
7) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered concurrently with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
8) Coumarin anticoagulants (warfarin, etc.): Warfarin and NSAIDs may have a synergistic effect on gastrointestinal bleeding, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
9) Cyclosporine and tacrolimus: Nephrotoxicity of cyclosporine and tacrolimus may increase when used together with non-steroidal anti-inflammatory drugs.
10) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
11) Corticosteroids: When used together with this drug, the risk of gastrointestinal ulcers or bleeding may increase.

7. Administration to pregnant and lactating women
1) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased fetal survival rate.
2) There is no clinical data on administering this drug to pregnant women. Like other non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered late in pregnancy. Do not administer to pregnant women in the last trimester of pregnancy.
3) Since the safety of administration during pregnancy has not been established, it should be administered to women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks. When using this drug, it should be administered at the lowest effective dose and shortest treatment period.
4) After using non-steroidal anti-inflammatory drugs in pregnant women, fetal renal dysfunction, decreased urine output, and accompanying oligohydramnios were reported. Pregnant women taking this drug should exercise caution, including monitoring amniotic fluid as needed.
5) Since milk secretion was reported in animal experiments (rats), this drug should not be administered during lactation.

8. Administration to children
Safety in children has not been established.

9. Administration to elderly people
As with other non-steroidal anti-inflammatory drugs, caution should be exercised when administering this drug to the elderly.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 9items

No.Product NameDetailsDate of ChangeDownload
9Loxonal Tab.Precautions for use2024.01.06PDFLoxonal Tablet Change Order_Change Plan + Change Comparison Table.pdf
8Loxonal Tab.Precautions for use2023.04.30PDF0013_200301612_Precautions for use (Roxonal tablet).pdf
7Loxonal Tab.Precautions for use2021.02.16HWPContents of permit change order_loxoprofen sodium.hwp
6Loxonal Tab.Precautions for use2018.12.24PDF0034_200301612_Precautions for use_Loxonal tablet.pdf
5Loxonal Tab.Loxonal Tablet (Precautions for use)2015.04.02HWPPermission change order (draft)_Precautions for use_Loxoprofen (
4Loxonal Tab.Loxonal Tablet (effectiveness, dosage, directions for use...2011.12.29HWPLoxonal Tablet Efficacy and Use_Dosage_Precautions for Use.hwp
3Loxonal Tab.Loxonal Tablet (Precautions for use)2009.10.07HWP9. Change order for permission (Roxonal) (2009.10.07).hwp
2Loxonal Tab.Loxonal Tablet (Precautions for use)2008.03.13HWP9. Change order for permission (Roxonal) (2008.03.13).hwp
1Loxonal Tab.Loxonal Tablet (Precautions for use)2006.02.02HWP9. Change order for permission (Roxonal) (2006.02.02).hwp